Noxopharm (CHIA:NOX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NOX Overzicht aandelen

Noxopharm Limited, een biotechbedrijf, ontdekt en ontwikkelt behandelingen voor kanker en ontstekingen, en mRNA-vaccins in Australië.

Over het bedrijf

NOX fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Earnings have declined by 9.5% per year over past 5 years

Volatile share price over the past 3 months

Does not have a meaningful market cap (A$35M)

Does not have meaningful revenue (A$2M)

Noxopharm Limited Concurrenten

Alterity Therapeutics

ASX:ATH

AU$21.3m

Cynata Therapeutics

ASX:CYP

AU$42.5m

Biotron

ASX:BIT

AU$17.1m

Patrys

ASX:PAB

AU$12.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Noxopharm
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.12
52 Week Hoogtepunt	AU$0.17
52 Week Laag	AU$0.044
Bèta	0.78
11 maand verandering	21.05%
3 maanden verandering	74.24%
1 Jaar Verandering	101.75%
33 jaar verandering	-78.50%
5 jaar verandering	-69.74%
Verandering sinds IPO	-37.84%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	NOX	AU Biotechs	AU Markt
7D	9.5%	0.4%	1.1%
1Y	101.8%	18.7%	17.9%

Rendement versus industrie: NOX exceeded the Australian Biotechs industry which returned 18.7% over the past year.

Rendement versus markt: NOX exceeded the Australian Market which returned 17.2% over the past year.

Prijsvolatiliteit

Is NOX's price volatile compared to industry and market?
NOX volatility
NOX Average Weekly Movement	13.5%
Biotechs Industry Average Movement	10.4%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: NOX's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: NOX's weekly volatility has decreased from 20% to 14% over the past year, but is still higher than 75% of Australian stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	n/a	Gisela Mautner	www.noxopharm.com

Noxopharm Limited, een biotechbedrijf, ontdekt en ontwikkelt behandelingen voor kanker en ontstekingen, en mRNA-vaccins in Australië. Het bedrijf ontwikkelt voornamelijk Veyonda, een formulering van idronoxil voor de behandeling van solide tumoren. Het bedrijf ontwikkelt ook LuPIN met gecombineerde therapie van Veyonda en 177Lu-PSMA-617 voor de behandeling van prostaatkanker in een laat stadium; en het IONIC-programma met Veyonda, dat wordt gecombineerd met de Bristol Myers Squibb checkpointremmer Opdivo voor de behandeling van verschillende vaste tumortypes.

Noxopharm Limited Samenvatting

Hoe verhouden de winst en inkomsten van Noxopharm zich tot de beurswaarde?
NOX fundamentele statistieken
Marktkapitalisatie	AU$35.07m
Inkomsten(TTM)	-AU$3.58m
Inkomsten(TTM)	AU$2.40m

14.6x

P/S-verhouding

-9.8x

Koers/Winstverhouding

Is NOX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NOX resultatenrekening (TTM)
Inkomsten	AU$2.40m
Kosten van inkomsten	AU$2.94m
Brutowinst	-AU$534.81k
Overige uitgaven	AU$3.04m
Inkomsten	-AU$3.58m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.012
Brutomarge	-22.28%
Nettowinstmarge	-149.07%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde NOX op de lange termijn?

Bekijk historische prestaties en vergelijking

NOX Overzicht aandelen

Beloningen

Risicoanalyse

Noxopharm Limited Concurrenten

ASX:ATH

AU$21.3m

ASX:CYP

AU$42.5m

ASX:BIT

AU$17.1m

ASX:PAB

AU$12.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Market cap size

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Recent updates

New major risk - Market cap size

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.70

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Noxopharm Limited Samenvatting

14.6x

-9.8x

Inkomsten en omzet